scholarly journals Impact of COVID-19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)

2022 ◽  
Vol 33 ◽  
Author(s):  
Yuya Nogami ◽  
Hiroaki Komatsu ◽  
Takeshi Makabe ◽  
Yuri Hasegawa ◽  
Yoshihito Yokoyama ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Gynecologic Oncology ◽  
Gynecologic Cancer ◽  
Nationwide Survey ◽  
Japan Society

Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer

1998 ◽  
pp. 253-276 ◽  
Author(s):  
Young B. Kim ◽  
Kris Ghosh ◽  
Steven Ainbinder ◽  
Jonathan S. Berek
Keyword(s):  
Gynecologic Oncology ◽  
Gynecologic Cancer

scholarly journals Approach to Palliative Care Consultation for Patients With Malignant Bowel Obstruction in Gynecologic Oncology: A Qualitative Analysis of Physician Perspectives

2020 ◽  
Vol 16 (8) ◽  
pp. 483-489
Author(s):  
Claire Hoppenot ◽  
Fay J. Hlubocky ◽  
Julie Chor ◽  
S. Diane Yamada ◽  
Nita K. Lee
Keyword(s):  
Palliative Care ◽  
Qualitative Analysis ◽  
Bowel Obstruction ◽  
Gynecologic Oncology ◽  
Gynecologic Cancer ◽  
Malignant Bowel Obstruction ◽  
Specific Patient ◽  
Palliative Care Consultation ◽  
Care Consultation ◽  
Nonsurgical Patients

PURPOSE: Malignant bowel obstruction (MBO) from gynecologic cancer is associated with increased symptoms and short survival. A gynecologic oncologist’s approach to palliative care consultation in the setting of MBO has not been well studied—it could be an opportune time for collaboration with palliative care. MATERIALS AND METHODS: This qualitative analysis of interviews with gynecologic oncologists focuses on their perspectives on palliative care consultation at the time of MBO. Interviews were analyzed using a framework analysis, and key themes and quotations were extracted. RESULTS: We interviewed 15 gynecologic oncologists from 8 institutions in Chicago. They described a variety of expectations from palliative care consultation. Most frequently, they consulted palliative care for specific questions but managed the remainder of the care. Most participants frequently consulted palliative care, but they also worried about fragmentation of care, the timing of when to introduce a new team during MBO, and the selection of appropriate patients for a limited resource. Many participants preferred earlier palliative care consultation, and many described an emotional toll of caring for patients with MBO. Palliative care consultation was most readily discussed for nonsurgical patients. CONCLUSION: Participants’ expectations of palliative care consultations during MBO varied and were not always met. We recommend strengthening communication and protocols for palliative care involvement that meet the needs of specific patient populations and physician teams for surgical and nonsurgical patients. More research is needed to better understand how to integrate palliative care into oncologic and surgical care with gynecologic oncologists.

Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

2018 ◽  
Vol 24 (1) ◽  
pp. 1-19 ◽  
Author(s):  
Yasuhiko Ebina ◽  
Mikio Mikami ◽  
Satoru Nagase ◽  
Tsutomu Tabata ◽  
Masanori Kaneuchi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Gynecologic Oncology ◽  
Uterine Cervical Cancer ◽  
Japan Society

Spirituality in gynecological oncology: a review

2004 ◽  
Vol 14 (2) ◽  
pp. 183-201 ◽  
Author(s):  
L. M. Ramondetta ◽  
D. Sills
Keyword(s):  
Cancer Treatment ◽  
Gynecologic Oncology ◽  
The Body ◽  
Women Patients ◽  
Oncology Patients ◽  
Gynecological Oncology ◽  
Common Thread ◽  
Reproductive Cancers ◽  
The Many

AbstractThe following is a review of some of the work that has been published on issues related to definitions of spirituality and the many ways in which religious or spiritual concerns inform and can sometimes mold the relationships between gynecologic oncology patients, their physicians, and their health. Moreover, we have raised the question whether there is something specific or unique to the experience of women patients with reproductive cancers? Although it might seem clear to many of us that these patients are unique, it is hard to say exactly why. While there are differences between the various types of reproductive cancers, all share a common thread and all undermine the patient's identity as a woman. For oncologists, exploring the connection between the healing of the body and the healing of the spirit recognizes the comprehensive character of cancer treatment, and furthers the understanding that both physicians and patients share a knowledge that what patients lose in their battle with cancer is more than simply a medical life.

The surprise question in gynecologic oncology: An analysis looking at end-of-life care in patients with gynecologic cancer

2020 ◽  
Vol 159 ◽  
pp. 313
Author(s):  
W. Barton ◽  
M. Cohen ◽  
C. Raker ◽  
C. Luis ◽  
R. Cram ◽  
...  
Keyword(s):  
End Of Life ◽  
End Of Life Care ◽  
Gynecologic Oncology ◽  
Gynecologic Cancer ◽  
Life Care ◽  
Surprise Question

Patterns of Care for Radiotherapy in Vulvar Cancer: A Gynecologic Cancer Intergroup Study

2009 ◽  
Vol 19 (1) ◽  
pp. 163-167 ◽  
Author(s):  
David K. Gaffney ◽  
Andreas Du Bois ◽  
Kailash Narayan ◽  
Nick Reed ◽  
Takafumi Toita ◽  
...  
Keyword(s):  
Vulvar Cancer ◽  
Gynecologic Oncology ◽  
Gynecologic Cancer ◽  
Neoadjuvant Treatment ◽  
Study Groups ◽  
Cooperative Groups ◽  
Computed Tomographic ◽  
Gynecology And Obstetrics ◽  
Initial Surgery ◽  
Individualize Treatment

Background:This study aimed to describe radiotherapeutic practice in the treatment of vulvar cancer in member study groups of the Gynecologic Cancer Intergroup (GCIG).Methods:A survey was developed and distributed to representatives of the member study groups of the GCIG, targeting the use of radiotherapy (RT) in vulvar cancer.Results:Thirty-two surveys were returned from 12 different cooperative groups. The most common indications for neoadjuvant RT include unresectable disease or International Federation of Gynecology and Obstetrics stage ≥III. For the neoadjuvant treatment of vulvar cancer, pelvic doses were 48.2 ± 5.0 Gy (mean ± SD). The upper border of the pelvic field was L4/5 in 4, L5/S1 in 12, and not specified in 4. Of 21 groups that perform neoadjuvant RT, 17 use concomitant chemotherapy and 4 individualize treatment. Weekly cisplatin was the most commonly used chemotherapy. For the neoadjuvant RT treatment of the inguinal region, doses were 49.9 ± 5.5 Gy (mean ± SD). Sixteen of 18 groups used computed tomographic simulation for planning. After initial surgery, the most common indications for RT included positive lymph nodes or positive margins. Chemotherapy was not routinely used after surgery.Conclusions:Doses of RT among GCIG members are similar; however, the indications for treatment, treatment fields, and use of chemotherapy differ somewhat between groups. This is likely due to the rarity of the disease. The lack of randomized trials may contribute to the absence of a broadly accepted standard. This underscores the importance of international cooperation as in GCIG to gather more reliable data for uncommon tumors in gynecologic oncology.

Sign in / Sign up

Export Citation Format

Share Document